Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and clinical activity of tadalafil,
pembrolizumab, ipilimumab, and CRS-207 in subjects with metastatic pancreatic adenocarcinoma
who have progressed after at least 1 prior chemotherapy regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins